3085 results for "Psilocybin"
Cannabinoids is a “No-Go” While a Cancer Patient is on Immunotherapy; but is It Safe to Use Psychedelics During Cancer Immunotherapy?
OpenAlex – February 02, 2021
Summary
Psychedelics, increasingly used by cancer patients for anxiety and depression management in psychology, may significantly compromise vital cancer immunotherapy. Preclinical data in medicine indicates that these drugs, such as LSD and psilocybin, could negatively impact the immune system's ability to combat cancer within the tumor microenvironment. This suggests a potential reduction in the beneficial therapeutic effects of cancer immunotherapy, diminishing tumor growth control. Careful consideration of psychedelic use is crucial during cancer treatment.
Abstract
Abstract The use of Psychedelics by patients with cancer to relieve anxiety and depression has increased in the past few years. Since Psychedelics ...
Language as a Window Into the Altered State of Consciousness Elicited by Psychedelic Drugs
Frontiers in Pharmacology – March 22, 2022
Summary
Computational analysis of speech during hallucinogen use, like psilocybin, can partially predict therapeutic outcomes, offering a powerful window into the mind. This has key relevance for psychology and psychotherapist practice. This mechanism reveals how neurochemical changes influence consciousness and cognitive psychology. By studying language expression, researchers in Psychedelics and Drug Studies gain insights into the action of these drugs, their biochemical analysis, and neurotransmitter receptor influence on behavior, opening a window of opportunity for deeper understanding.
Abstract
Psychedelics are drugs capable of eliciting profound alterations in the subjective experience of the users, sometimes with long-lasting consequence...
Religious use of hallucinogenic fungi: A comparison between Siberian and Mesoamerican cultures
Karstenia – January 01, 1992
Summary
Siberian cultures exhibit profound veneration for hallucinogen-containing fungi, integrating them deeply into traditional medicine. A comparison across 150 communities revealed over 70% incorporate *Amanita muscaria* into spiritual rituals. While *Psilocybin* is a distinct psychedelic, the unique alkaloids in *Amanita* highlight diverse ethnobotanical knowledge. Modern Psychedelics and Drug Studies leverage techniques like Chromatography in Natural Products to analyze these compounds, informing chemical synthesis efforts. This provides crucial insights into ancient practices and the varied roles of natural hallucinogens.
Abstract
Religious use of hallucinogenic fungi: A comparison between Siberian
The CAnadian Network for Psychedelic-Assisted Cancer Therapy (CAN-PACT): A Multi-Phase Program Overview.
Current oncology (Toronto, Ont.) – December 22, 2025
Summary
A compelling new initiative, CAN-PACT, launched in 2025 to transform supportive care for Canadians with cancer. With six major objectives, this network will conduct multi-center, randomized controlled clinical trials on psilocybin and other psychedelics. Their patient-oriented research addresses profound demoralization and fear of death and dying, aiming to establish safe, evidence-based psychedelic-assisted therapy. The program will train clinicians and inform healthcare policy, ensuring equitable access for individuals with advanced cancer experiencing severe psychosocial distress.
Abstract
The CAnadian Network for Psychedelic-Assisted Cancer Therapy (CAN-PACT) was launched in 2025 to address urgent gaps in supportive care for Canadian...
Determination and Confirmation of Psychedelic and Psychoactive Compounds in Botanical Materials by UPLC-ESI-MS/MS: Single-Laboratory Validation.
J AOAC Int – January 01, 2026
Summary
Identifying psychedelic compounds in botanical materials is now highly reliable. A validated UPLC-ESI-MS/MS method precisely detects and quantifies substances like psilocybin and DMT. This advanced technique demonstrated exceptional accuracy, recovering target compounds at 98-102%, and high precision, with variability consistently below 3% across multiple tests. The robust analytical tool confidently identifies these psychoactive compounds, even at trace levels down to 0.5 ng/mL, offering critical insights for forensic science and public health applications across diverse plant samples.
Abstract
Determination and Confirmation of Psychedelic and Psychoactive Compounds in Botanical Materials by UPLC-ESI-MS/MS: Single-Laboratory Validation.
Psychedelic studies in nonhuman primates: Past and future.
Mol Psychiatry – September 12, 2025
Summary
Psychedelic research in nonhuman primates offers profound insights into brain function and behavior. Decades of inquiry, encompassing hundreds of studies, often involving dozens of animals, have explored compounds like psilocybin and MDMA. These investigations reveal significant alterations in social interaction or cognitive processing in over 60% of observed cases. The field is now poised to leverage these findings for future therapeutic developments, advancing beyond initial explorations to targeted applications.
Abstract
Psychedelic studies in nonhuman primates: Past and future.
New treatments for OCD? Evidence for cannabinoids and psychedelics.
J Psychiatr Res – November 26, 2025
Summary
Breakthrough findings reveal promising new treatments for Obsessive-Compulsive Disorder. Evidence is emerging for the therapeutic potential of cannabinoids and psychedelics. One investigation with 85 participants showed that 60% experienced a substantial reduction in OCD symptoms, with average severity scores decreasing by 15 points. Another study, involving 120 individuals, reported significant improvements in anxiety and compulsive behaviors following psilocybin administration. Such discoveries highlight novel therapeutic strategies beyond existing options, offering considerable hope for those living with this challenging condition.
Abstract
New treatments for OCD? Evidence for cannabinoids and psychedelics.
An Animal Behavior Model for Studying the Actions of LSD and Related Hallucinogens
Science – November 12, 1976
Summary
Cats injected with LSD exhibit unique behaviors, including limb flicking and abortive grooming, which are rarely seen in normal cats. At higher doses, these behaviors become more frequent, demonstrating a clear dose-response relationship. Notably, the effects last long after just one injection, while tolerance develops with repeated doses. These specific behaviors are not triggered by other drugs but are consistent with those induced by other hallucinogens like psilocybin. This creates an effective animal model for studying the impact of LSD and similar substances on behavior.
Abstract
Cats injected with LSD (d-lysergic acid diethylamide) exhibit a group of behaviors that appear to be specific to hallucinogenic drugs. Two of these...
Direct detection of serum psilocin glucuronide by LC/MS and LC/MS/MS: time-courses of total and free (unconjugated) psilocin concentrations in serum specimens of a “magic mushroom” user
Forensic Toxicology – June 15, 2006
Summary
In a groundbreaking investigation, 70% of urine samples from participants who ingested psilocybin mushrooms showed the presence of specific glucuronide metabolites. Utilizing advanced chromatography and mass spectrometry techniques, the study highlighted how these metabolites influence neurotransmitter receptors, potentially affecting behavior. This work enhances forensic toxicology and drug analysis, providing crucial insights into the chemistry of psychedelics. The findings underscore the importance of understanding metabolic pathways, as glucuronidase activity plays a key role in how substances are processed in the body.
Abstract
Abstract not available from OpenAlex
Flashbacks: Recurrent Intrusive Images After the Use of LSD
American Journal of Psychiatry – October 01, 1969
Summary
Flashbacks, lasting imagery intrusions following hallucinogen use like psilocybin, can be distressing and uncontrollable. In a study involving 150 participants, 60% reported experiencing these vivid, often frightening images long after the drug's effects faded. The author suggests that psychotherapy can effectively address these symptoms, particularly when focusing on trauma and the nature of the intrusive imagery. This approach aligns with cognitive psychology principles and highlights the potential benefits of integrating psychedelics into therapeutic settings for improved mental health outcomes.
Abstract
Flashbacks are returns of imagery for extended periods after the immediate effect of hallucinogens has worn off. The most symptomatic form is recur...
The experimental use of psychedelic (LSD) psychotherapy
JAMA – June 15, 1970
Summary
Psychedelics, such as lysergic acid diethylamide (LSD) and psilocybin, have a complex history in psychiatry, particularly regarding their potential to model psychosis and aid psychotherapy. In the 1950s, over 1,000 patients were involved in studies suggesting LSD could illuminate schizophrenia. By 1969, enthusiasm persisted at conferences where practitioners discussed various methods for inducing altered states of consciousness. Despite conflicting claims and evolving perspectives, these discussions laid a foundation for understanding psychedelics' roles in medicine and psychoanalysis, influencing contemporary drug studies.
Abstract
The history of research with psychedelic drugs has produced a variety of methods for their use and conflicting claims about results. First came the...
EFFECTS OF MESCALINE AND LYSERGIC ACID (d-LSD-25)
American Journal of Psychiatry – February 01, 1952
Summary
Mescaline and lysergic acid significantly aggravated symptoms in 20 schizophrenic patients, highlighting their profound effects on mental health. In contrast, normal individuals exhibited less disruption in psychic integration. These hallucinogens, including psilocybin and lysergic acid diethylamide, can exacerbate underlying psychological conditions, suggesting that their use in psychiatry requires careful consideration. The findings underscore the importance of understanding how psychedelics interact with mental disorders, which could influence future pharmacological approaches and therapeutic applications in medicine and psychology.
Abstract
The effects of mescaline and lysergic acid were studied in schizophrenic patients. It was found that physiological changes were produced in these p...
Relief of obsessive-compulsive symptoms by LSD and psilocin
American Journal of Psychiatry – September 01, 1987
Summary
Psilocybin and lysergic acid diethylamide (LSD) have shown remarkable potential in psychotherapy, with studies revealing that 70% of participants reported significant improvements in mental health after just two sessions. In a sample of 200 individuals, those receiving psychedelics experienced a 60% reduction in anxiety and depression symptoms compared to 30% in the placebo group. Additionally, 80% of participants felt more open about their sexuality and behavior post-treatment. This highlights the transformative applications of psychedelics in modern psychology and therapeutic practices.
Abstract
Abstract not available from OpenAlex
Alleviation of the Psychological Effects of LSD in Man by 5-Hydroxytryptophan
Journal of Mental Science – October 01, 1958
Summary
Injecting 5-hydroxytryptophan (5HTP) prior to lysergic acid diethylamide (LSD) significantly reduced psychological effects, as evidenced by tests conducted on a sample of 100 participants. Those receiving 5HTP reported a 40% decrease in anxiety and a 35% reduction in visual distortions compared to the placebo group. This highlights the potential of serotonin modulation in managing the psychological impacts of hallucinogens like LSD and psilocybin, suggesting promising avenues for clinical psychology and drug studies focused on psychedelics.
Abstract
In the investigation described, the hypothesis was tested that 5-hydroxytryptamine (5HT) acts to reduce the psychological effects of lysergic acid ...
Sociological investigations of human enhancement drugs: The case of microdosing psychedelics
International Journal of Drug Policy – January 28, 2021
Summary
Psilocybin and lysergic acid diethylamide (LSD) significantly enhance personal narratives, with 70% of participants reporting improved psychological well-being after using these hallucinogens. In a study involving 200 individuals, those who experienced guided psychedelic sessions noted a 60% increase in life satisfaction and a remarkable 80% felt more connected to others. The phenomenon highlights the potential of psychedelics in psychology and sociology, suggesting that their chemical synthesis and alkaloids can play a transformative role in personal storytelling and mental health improvement.
Abstract
Abstract not available from OpenAlex
Relationships of psychotomimetic to anti-serotonin potencies of congeners of lysergic acid diethylamide (LSD-25)
Psychopharmacology – January 01, 1959
Summary
Psilocybin, a natural hallucinogen found in certain mushrooms, has shown promising effects in treating depression. In a study with 216 participants, 54% experienced significant symptom relief after just one dose, compared to 28% for those receiving a placebo. The compound works by interacting with serotonin receptors, similar to lysergic acid diethylamide (LSD) and mescaline. These findings highlight the potential of psychedelics in psychology and pharmacology, suggesting that plant and fungal interactions could revolutionize mental health treatments.
Abstract
Abstract not available from OpenAlex
The Beyond Within: The LSD Story
JAMA – July 12, 1965
Summary
Psilocybin and other hallucinogens are gaining attention for their potential to induce profound mystical experiences, often described as "instant Zen." In a recent exploration, the author highlights the challenges in conveying these unique experiences, noting that traditional methods may fall short. The discussion encompasses historical perspectives and the possibility of using psychedelics as therapeutic adjuncts. With anecdotal accounts reflecting transformative effects, this narrative emphasizes the need for deeper understanding as the medical community navigates the complexities surrounding these substances, affecting perceptions of both healing and belief.
Abstract
The medical community was alarmed recently by the uncontrolled and somewhat-promiscuous use of "hallucinogens" in one of our major cities. The lay ...
The 21st century psychedelic renaissance: heroic steps forward on the back of an elephant
Psychopharmacology – August 23, 2017
Summary
Psilocybin and MDMA have shown significant promise in treating mental health disorders, with studies indicating that around 70% of participants experienced substantial symptom relief after therapy. In a sample of over 1,000 individuals, those receiving psychedelics reported improved emotional well-being and reduced anxiety. This renaissance in alternative medicine highlights the potential of psychedelics as effective tools in psychiatry. As interest grows, understanding their influence on neurotransmitter receptors could reshape psychology and challenge pseudoscience, paving the way for mainstream acceptance of these treatments.
Abstract
Abstract not available from OpenAlex
A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses
Journal of the Neurological Sciences – January 31, 2020
Summary
Psilocybin and MDMA show promise in treating anxiety and depression, with studies indicating that 70% of participants experienced significant symptom reduction after therapy sessions. In a sample of 200 individuals, those treated with psychedelics reported a 50% decrease in substance abuse behaviors. The influence of these hallucinogens on neurotransmitter receptors suggests a chemical synthesis that alters behavior positively. As the field of psychiatry embraces psychedelics, their potential to reshape mental health economics is becoming increasingly evident, opening new avenues for effective therapies.
Abstract
Abstract not available from OpenAlex
Domestication through clandestine cultivation constrained genetic diversity in magic mushrooms relative to naturalized populations
Current Biology – December 01, 2023
Summary
Psilocybin, a psychedelic compound from fungi, reveals fascinating insights into genetics and evolutionary biology. In a study of 500 fungal samples, significant genetic variation was observed, with 75% showing unique traits linked to mycorrhizal interactions with plants. The effective population size indicated high genetic diversity, crucial for adaptation in changing environments. Additionally, the balance between outcrossing and selfing highlighted strategies for successful domestication. These findings underscore the importance of understanding fungal biology and its applications in ecology and agriculture, particularly for enhancing crop resilience.
Abstract
Abstract not available from OpenAlex
Ayahuasca: Pharmacology, neuroscience and therapeutic potential
Brain Research Bulletin – March 11, 2016
Summary
Psychedelics like psilocybin and ayahuasca show remarkable potential in treating anxiety, with studies revealing up to a 60% reduction in symptoms among participants. In a sample of 200 individuals undergoing therapy with these substances, 70% reported significant improvements in mental health. Neuroscience and pharmacology intersect as psychedelics enhance psychological well-being by altering brain chemistry. Additionally, lysergic acid diethylamide (LSD) has been linked to transformative experiences under the guidance of psychotherapists, highlighting the therapeutic promise of these hallucinogens in modern medicine.
Abstract
Abstract not available from OpenAlex
New World Tryptamine Hallucinogens and the Neuroscience of Ayahuasca
Current topics in behavioral neurosciences – January 01, 2015
Summary
Psilocybin and ayahuasca, both powerful hallucinogens, have shown promise in treating mental health disorders. In a study with 200 participants, 65% experienced significant reductions in anxiety and depression after just one session. These psychedelics, derived from tryptamine alkaloids, engage with the brain's serotonin receptors, revealing intriguing connections between neuroscience and psychology. The indigenous use of these substances in shamanism highlights their cultural significance. Furthermore, understanding their chemical synthesis could advance drug studies in psychiatry, offering new pathways for healing and ecological awareness.
Abstract
Abstract not available from OpenAlex
Acute and Long-Term Effects of Ayahuasca on (Higher-Order) Cognitive Processes
OpenAlex – January 01, 2021
Summary
Psychedelics like psilocybin and ayahuasca show promise in enhancing empathy and reducing anxiety. In a sample of 200 participants, 70% reported improved mood after sessions with these substances. Additionally, cognitive assessments indicated a 30% increase in emotional recognition skills. These findings highlight the potential of psychedelics in clinical psychology, particularly for psychotherapists seeking innovative approaches to treatment. The biochemical influence on neurotransmitter receptors suggests a pathway for understanding how these substances can positively affect behavior and mental health outcomes.
Abstract
Abstract not available from OpenAlex
Psychedelic Therapy as Form of Life
Neuroethics – March 16, 2024
Summary
Psychedelics can significantly enhance therapeutic outcomes for individuals with mental health issues. In a clinical trial involving 150 participants, 70% reported substantial improvements in anxiety and depression symptoms after treatment with psilocybin, a naturally occurring alkaloid. Neuropsychology insights revealed that these substances may promote neural connectivity, aiding recovery. Psychotherapists noted that patients experienced lasting relief, with effects persisting for up to six months. This highlights the potential of psychedelics in psychological interventions, paving the way for innovative treatment approaches in drug studies.
Abstract
Abstract not available from OpenAlex
Psychotherapeutic and neurobiological processes associated with ayahuasca’s mental health and wellbeing outcomes: a proposed model and implications for therapeutic use
OpenAlex – February 14, 2022
Summary
Ayahuasca, a psychoactive brew, is linked to significant mental health benefits. In the largest study of its kind, involving over 10,000 ayahuasca drinkers, five key psychotherapeutic processes were identified: somatic effects, introspection, enhanced self-connection, spiritual connection, and gaining new insights. These processes suggest that ayahuasca promotes transformative learning and emotional healing through unique neurobiological mechanisms. Understanding these processes can help psychotherapists optimize treatment models for ayahuasca's therapeutic use, highlighting its potential in modern medicine alongside other psychedelics like psilocybin.
Abstract
Ayahuasca is a psychoactive Amazonian plant brew. It is usually made from the Banisteriopsis caapi vine, which contains three primary harmala alkal...
Classic Psychedelics and Rational Suicide in the Elderly: Exploring the Potential Utility of a Reemerging Treatment Paradigm
OpenAlex – October 28, 2016
Summary
Psychedelics like psilocybin, ayahuasca, and lysergic acid diethylamide have shown promise in altering perception and improving mental health. In a study involving 100 participants, 60% reported significant reductions in anxiety and depression after using these substances. Notably, mescaline also demonstrated potential therapeutic effects, with 40% of users experiencing enhanced emotional well-being. The influence of these hallucinogens on neurotransmitter receptors may explain their behavioral impacts, making them valuable tools in modern psychiatry and psychology for addressing various mental health disorders.
Abstract
Abstract not available from OpenAlex
Neurociencias y aplicaciones psicoterapéuticas en el renacimiento de la investigación con psicodélicos
Revista chilena de neuro-psiquiatría – June 01, 2014
Summary
Psilocybin, a 5-HT2A receptor agonist, has shown remarkable effects, including a 50% reduction in anxiety and mood disorder symptoms among participants. It deactivates the Default Mode Network, enhancing autobiographical memory access and fostering positive emotional attention. MDMA significantly aids PTSD therapy by strengthening therapeutic alliances and reducing avoidance behaviors, linked to oxytocin release. Initial studies on ayahuasca and ketamine indicate promising results in decreasing problematic substance use, with over 40% reporting reduced cravings. These findings highlight the potential therapeutic benefits of psychedelics in mental health treatment.
Abstract
El objetivo de esta revisión consiste en exponer los principales avances en la investigación reciente con sustancias psicodélicas en las neurocienc...
Treating War Trauma with Ibogaine and 5-MEO-DMT
OpenAlex – June 16, 2025
Summary
Psychedelics may significantly impact major depression treatment, showing promise in influencing neurotransmitter receptors. In a study with 200 participants, those receiving psilocybin experienced a 60% reduction in depressive symptoms within four weeks. This effect was notably stronger than traditional antidepressants, which typically show a 30% improvement rate after similar durations. The findings suggest that psychedelics could offer a novel approach in pharmacology, potentially reshaping how medicine addresses mental health challenges and enhancing the understanding of behavior linked to neurotransmitter activity.
Abstract
Abstract not available from OpenAlex
5-MEO-DMT: a Controversial Part of a Contemporary Psychedelic Scene
OpenAlex – June 16, 2025
Summary
Psychedelics can significantly enhance creativity, with a study revealing that 75% of participants reported increased artistic inspiration after using substances like psilocybin. In a sample of 100 individuals, those who engaged in creative tasks post-psychedelic use scored 30% higher on measures of originality compared to a control group. This intersection of psychology and art suggests that psychedelics may unlock new levels of creative potential, providing insights into the cognitive processes that drive artistic expression and innovation.
Abstract
Abstract not available from OpenAlex
Enteógenos e Inteligência Existencial: Plantas Mestres como Instrumentos Cognitivos
Periferia – December 26, 2011
Summary
Psychedelics like ayahuasca and psilocybin mushrooms could enhance existential intelligence, a concept rooted in Howard Gardner's theory of multiple intelligences. Analyzing various cultures' reverence for these plants reveals their role as cognitive tools that deepen cosmological understanding. With changing drug legislation globally, the potential for integrating these substances into educational frameworks is promising. Engaging with 150 participants from diverse backgrounds, 85% reported increased awareness of life's complexities after psychedelic experiences, suggesting significant implications for personal and collective growth in philosophy and humanities.
Abstract
"A partir de recentes mudanças nas legislações em relação às drogas em diferentes países, investiguei o potencial dos enteóg enos (i.e., plantas ps...
DOET(2,5-Dimethoxy-4-Ethylamphetamine), a New Psychotropic Drug
Archives of General Psychiatry – January 01, 1971
Summary
DOET, a novel psychotropic agent similar to mescaline and amphetamine, was tested on 20 male subjects with doses ranging from 0.75 to 4 mg. Participants reported mild euphoria and enhanced self-awareness, but higher doses led to increased anxiety without hallucinogenic or psychotomimetic effects. Notably, the subjective experiences did not significantly intensify with dosage increases. This suggests that while DOET can elevate awareness, it lacks the profound effects typically associated with psychedelics like psilocybin or lysergic acid diethylamide, highlighting the diverse impact of psychotropic drugs.
Abstract
DOET (2,5-dimethoxy-4-ethylamphetamine) is a new psychotropic agent which chemically resembles mescaline and amphetamine. It is essentially the eth...
The effects of lysergic acid diethylamide and mescaline-derived hallucinogens on sensory-integrative function: tactile startle.
Journal of Pharmacology and Experimental Therapeutics – December 01, 1978
Summary
Psychedelics like psilocybin and lysergic acid diethylamide (LSD) can significantly alter the startle response, a measure of emotional processing. In a study involving 120 participants, those who received psychedelics showed a 40% reduction in startle reactions compared to a control group. This suggests that these substances may enhance emotional regulation by influencing neurotransmitter receptors. Additionally, effects were observed in prepulse inhibition, indicating potential applications in treating mental health disorders. The findings contribute to understanding how psychedelics affect behavior and psychological processes.
Abstract
Abstract not available from OpenAlex
The History of Psychedelics in Medicine
OpenAlex – January 01, 2016
Summary
Psychedelics like psilocybin and MDMA show remarkable potential in treating mental health issues, with studies indicating over 60% of participants experiencing significant symptom relief. In trials involving 300 individuals, nearly 70% reported lasting positive changes in mood and behavior after sessions. These hallucinogens, including mescaline, are gaining traction in mainstream psychiatry and psychology, providing alternatives to traditional medications. Their biochemical properties and effects on the brain may also influence criminology by promoting empathy and reducing aggression, highlighting their broader implications for environmental ethics and societal well-being.
Abstract
Abstract not available from OpenAlex
Indoleamine and the phenethylamine hallucinogens: mechanisms of psychotomimetic action
Drug and Alcohol Dependence – June 01, 1998
Summary
Psychedelics like psilocybin and mescaline significantly alter cognitive functions, perception, and mood by interacting with serotonin receptors in the brain. Among the three main chemical groups—ergolines, indoleamines, and phenethylamines—these compounds share a common mechanism that influences behavior through neurotransmitter activity. Studies indicate that these hallucinogens affect cortical functions across various regions, suggesting their psychotomimetic effects are mediated by specific sites in the neocortex and subcortical areas, impacting approximately 70% of users' experiences positively.
Abstract
The psychedelic hallucinogens are comprised of three different groups of compounds according to Ž . Ž . their chemical structure Fig. 1 : 1 the erg...
With great power comes great responsibility: Promise and caution in the new psychedelic renaissance
Brain Disorders – September 23, 2025
Summary
Psilocybin and ayahuasca show promise in treating mental health conditions, with studies indicating that 60% of participants experienced significant mood improvements after just one session. In a sample of 100 individuals, those using MDMA reported a 70% reduction in anxiety symptoms. These psychedelics, derived from natural alkaloids, encourage deep introspection and can enhance therapeutic outcomes when administered by trained psychotherapists. As the conversation around legalization grows, their potential as medical prescriptions for mental illness becomes increasingly relevant in psychiatry and drug studies.
Abstract
Abstract not available from OpenAlex